Cadila Of India To Reveal Soon New Breakthrough Drug Candidate
This article was originally published in PharmAsia News
Executive Summary
India's Cadila Pharmaceuticals says it plans to introduce soon a drug it expects to lower by one-third the cost of treating tuberculosis. Cadila said it expects to announce the drug Resorine (resorcin) within the next two weeks. Chairman I.A. Modi called the drug a bio-enhancer capable of lowering the dosage of existing TB drugs without sacrificing efficacy. The Cadila drug already has completed Phase III trials and has special protocol approval by U.S. FDA. The Cadila announcement comes just three months after it unveiled its Polycap (atenolol/thiazide) cardiac drug, which it considers a potential blockbuster. (Click here for more